
Sarepta denies Elevidys is linked to latest patient death in Brazil
Miyako Nakamura Shortly after the U.S. FDA announced an investigation into the death of a patient who had received Elevidys, a gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT), the company said that the death reported in Brazil is unrelated to